End-organ damage: Does it really matter how we prevent it?

European Heart Journal, Supplement

Volumn 5, Issue F, 2003, Pages

  Dahlöf, Björn ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endothetial dysfunction; Left ventricutar hypertrophy; Renin angiotensin aldosterone system; Target organ damage; Treatment

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DRUG EFFECT; ENDOTHELIUM; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HUMAN; HYPERTENSION; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TARGET ORGAN;

EID: 0042974084     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90014-9     Document Type: Conference Paper

References (47)

1. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997;11:213-20.
2. Smith WC, Lee AJ, Crombie IK, et al. Control of blood pressure in Scotland: the rule of halves. BMJ 1990;300:981-3.
3. Pannarale G, Gaudio C, Cristina Acconcia M, et al. Results of antihypertensive treatment by primary and secondary care physicians as assessed by ambulatory blood pressure monitoring. Blood Press Monit 2000;5:223-6.
4. Cruickshank JK, Mbanya JC, Wilks R, et al. Hypertension in four African-origin populations: current 'rule of halves', quality of blood pressure control and attributable risk of cardiovascular disease. J Hypertens 2001;19:41-6.
5. Weinehall L, Ohgren B, Persson M, et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens 2002;20:2081-8.
6. Teo KK. Risk and management of hypertension-related left ventricular hypertrophy. Drugs 1995;50:959-70.
7. Swates JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999;138(3 Pt 2):S231-7.
8. Weir MR. When antihypertensive monotherapy fails: fixed-dose combination therapy. South Med J 2000;93:548-56.
9. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
10. Zhu YC, Zhu YZ, Gohlke P, et al. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol 1997;80(suppl A):110A-7A.
11. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997;10:705-13.
12. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenotol. Lancet 2002;359:995-1003.
13. Okin PM, Devereux RB, Jern S, et al. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens 2001;14:775-82.
14. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenotol. Lancet 2002;359:1004-10.
15. Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenotol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002;20:1855-64.
16. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-35.
17. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricutar chamber stiffness in hypertensive patients. Circulation 2002;105:2512-7.
18. Mesfin GM, Piper RC, DuCharme DW, et al. Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol 1989;17:164-81.
19. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
20. Ikeda Y, Nakamura T, Takano H, et al. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. J Lab Clin Med 2000;135:353-9.
21. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.
22. Isobe N, Taniguchi K, Oshima S, et al. Candesartan citexetit improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002;66:993-9.
23. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001;14:174-82.
24. Wienen W, Entzeroth M, Diederen W, et at. Pharmacology and antihypertensive effects of telmisartan an AT1-selective angiotensin II receptor antagonist. In 1st International Symposium on Angiotensin II Antagonism. 1997. London, 28 September-1st October 1997.
25. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002;302:1089-95.
26. Burnier M, Maittard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001;10 (suppl 1):6-11.
27. Stangier J, Su C-APF, van Heiningen PNM, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001;38:672-85.
28. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-29.
29. Smith DHG, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-90.
30. White W. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003 (in press).
31. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptor [abstract P1.24]. J Hypertens 2001;19(suppl 2):S27.
32. Böhm M, Lippoldt A, Wienen W, et al. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996;163/164:217-21.
33. Wagner J, Drab M, Bohlender J, et al. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998;20:205-21.
34. Wienen W, Richard S, Champeroux P, et al. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2001;2:31-6.
35. Amende I, Chu V, Morgan JP, et al. Angiotensin II AT1 receptor blockade attenuates isoproterenol-induced cardiac hypertrophy in mice [abstract P2161]. Eur Heart J 2000;21 (abstract suppl):401.
36. Mattioli AV, Fontanesi L, Bonatti S, et al. Effects of regression of left ventricular hypertrophy on diastolic function in hypertensive patients. Am J Hypertens 2002;15(suppl 1): A44.
37. Petrovic J, Popovic Z, Petrovic D, et al. Telmisartan: influence on endothelial dysfunction in hypertensive patients [abstract PA.17]. J Renin Angiotensin Aldosterone Syst 2000;1:74.
38. Petrovic J, Petrovic M, Petrasinovic Z, et al. Ventricular and vascular remodeling: effects inhibitors ACE and AII receptor antagonists in hypertensive patients [abstract]. Atherosclerosis 2000;151:229.
39. Ivanova OV, Fomicheva OA, Sergakova LM, et al. Angiotensin II receptor blocker telmisartan: effect on 24-hour blood pressure profile and left ventricular hypertrophy in patients with hypertension. Kardiologlia 2002;42:45-9.
40. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995;8:221-8.
41. Willeit J, Kiechl S. Biology of arterial atheroma. Cerebrovasc Dis 2000;10(suppl 5):1-8.
42. Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 2001;7:1075-85.
43. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
44. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
45. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999;60:650-60.
46. Mancia G, Carugo S, Grassi G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension 2002;39:744-9.
47. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89 (suppl 2A):18A-25A.